Accueil>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>BGC 20-1531 (hydrochloride)

BGC 20-1531 (hydrochloride) (Synonyms: PGN 1531)

Catalog No.GC42927

BGC 20-1531 is a potent and selective antagonist of the prostaglandin E2 receptor subtype 4 (EP4) with Ki values of 11.7, >10,000, and >10,000 nM for EP4, EP2, and EP3, respectively.

Products are for research use only. Not for human use. We do not sell to patients.

BGC 20-1531 (hydrochloride) Chemical Structure

Cas No.: 1962928-26-2

Taille Prix Stock Qté
500μg
43,00 $US
En stock
1mg
69,00 $US
En stock
5mg
301,00 $US
En stock
10mg
472,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BGC 20-1531 is a potent and selective antagonist of the prostaglandin E2 receptor subtype 4 (EP4) with Ki values of 11.7, >10,000, and >10,000 nM for EP4, EP2, and EP3, respectively. It is selective for EP4, exhibiting <50% inhibition at 47 ion channels, cell-surface transporters, enzymes, and nuclear receptors at a concentration of 10 μM. BGC 20-1531 antagonizes PGE2-induced cAMP accumulation in a dose-dependent manner in HEK293 EBNA cells that stably express human EP4 receptors. It also reverses PGE2-induced vasorelaxation (Kb = 15.85 nM) in human middle cerebral and middle meningeal arterial rings. BGC 20-1531 prevents PGE2-induced increases in carotid blood flow and decreases in carotid resistance with an ID50 value of 5 mg/kg in dogs.

Avis

Review for BGC 20-1531 (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BGC 20-1531 (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.